Radioimmunotherapy with radioactive nanoparticles: First results of dosimetry for vascularized and necrosed solid tumors

Medical Physics

Volumn 34, Issue 11, 2007, Pages 4504-4513

  Bouchat, V ^a   Nuttens, V E ^a   Lucas, S ^a   Michiels, C ^a   Masereel, B ^a   Feron O ^b   Gallez, B ^b   Borght, T Vander ^b  

^a UNIVERSITY OF NAMUR   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Dosimetry; Monte Carlo; Nanomedicine; Radioimmunotherapy; Tumor model

Indexed keywords

CELL DEATH; DOSIMETRY; MEDICAL NANOTECHNOLOGY; MONOCLONAL ANTIBODIES; MONTE CARLO METHODS; NANOPARTICLES; RADIOACTIVITY; RADIOISOTOPES; RADIOTHERAPY;

BETA-EMITTING RADIONUCLIDES; DEPOSITED DOSE; NONUNIFORMITY; RADIOACTIVE ATOMS; RADIOIMMUNOTHERAPY; SOLID TUMORS; TUMOR CELLS; TUMOR MODELS;

TUMORS;

MONOCLONAL ANTIBODY; NANOPARTICLE; RADIOACTIVE MATERIAL; RADIOISOTOPE;

ARTICLE; CANCER; DOSIMETRY; ISOTOPE LABELING; MONTE CARLO METHOD; NECROSIS; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; SIMULATION; SOLID TUMOR; STATISTICAL MODEL; THERAPY EFFECT; TUMOR CELL; VASCULARIZATION;

EID: 35648966507     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.2791038     Document Type: Article

References (67)

1. D. M. Goldenberg, " Targeted therapy of cancer with radiolabeled antibodies., " J. Nucl. Med. 43, 693-713 (2002).
2. D. M. Goldenberg and R. M. Sharkey, " Advances in cancer therapy with radiolabeled monoclonal antibodies., " Q. J. Nucl. Med. Mol. Imaging 50, 248-264 (2006).
3. T. A. Waldmann, " Immunotherapy: Past, present and future., " Nat. Med. 9, 269-277 (2003).
4. P. Carmeliet, " Angiogenesis in health and disease., " Nat. Med. 9, 653-660 (2003).
5. J. Folkman, " Angiogenesis in cancer, vascular, rheumatoid and other disease., " Nat. Med. 1, 27-31 (1995).
6. J. Ahlskog, G. Paganelli, and D. Neri, " Vascular tumor targeting., " Q. J. Nucl. Med. Mol. Imaging 50, 296-309 (2006).
7. A. Gruaz-Guyon, O. Raguin, and J. Barbet, " Recent advances in pretargeted radio-immunotherapy., " Curr. Med. Chem. 12, 319-338 (2005).
8. E. J. Postema, O. C. Boerman, W. J. Oyen, J. M. Raemaekers, and F. H. Corstens, " Radioimmunotherapy of B-cell non-Hodgkin's lymphoma., " Eur. J. Nucl. Med. 28, 1725-1735 (2001).
9. T. E. Witzig, " Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma., " Cancer Chemother. Pharmacol. 48, 91S-95S (2001).
10. C. A. White, J. R. Berlfein, and A. J. Grillo-Lopez, " Antibody-targeted immunotherapy for treatment of non-Hodgkin's lymphoma., " Curr. Pharm. Biotechnol. 1, 303-312 (2000).
11. D. M. Goldenberg, " The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy., " Crit. Rev. Oncol. Hematol. 39, 195-201 (2001).
12. G. A. Wiseman, C. A. White, R. B. Sparks, W. D. Erwin, D. A. Podoloff, D. Lamonica, N. L. Bartlett, J. Anthony Parker, W. L. Dunn, S. M. Spies, R. Belanger, T. E. Witzig, and B. R. Leigh, " Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma., " Crit. Rev. Oncol. Hematol. 39, 181-194 (2001).
13. W. A. Bethge and B. M. Sandmaier, " Targeted cancer therapy using radiolabeled monoclonal antibodies., " Technol. Cancer Res. Treat. 4, 393-405 (2005).
14. S. V. Govindan, G. L. Griffiths, H. J. Hansen, I. D. Horak, and D. M. Goldenberg, " Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies., " Technol. Cancer Res. Treat. 4, 375-391 (2005).
15. R. M. Sharkey and D. M. Goldenberg, " Perspectives on cancer therapy with radiolabeled monoclonal antibodies., " J. Nuc. Med. Treat. 46, 115S-127S (2005).
16. D. M. Goldenberg, " Advancing role of radiolabeled antibodies in the therapy of cancer., " Cancer Immunol. Immunother 52, 281-296 (2003).
17. D. L. Peng, T. Hihara, and K. Sumiyama, " Structure and magnetic properties of FePt alloy cluster-assembled film., " J. Magn. Magn. Mater. 277, 201-208 (2004).
18. A. L. Thomann, J. P. Salvetat, Y. Breton, C. Andreazza-Vignolle, and P. Brault, " Thermal stability of metal nanoclusters formed by low-pressure plasma sputtering., " Thin Solid Films 428, 242-247 (2003).
19. A. Naudon, D. Babonneau, D. Thiaudìre, and S. Lequien, " Grazing-incidence small-angle x-ray scattering applied to the characterization of aggregates in surface regions., " Physica B 283, 69-74 (2000).
20. Y. Saito, " Nanoparticles and filled nanocapsules., " Carbon 33, 979-988 (1995).
21. S. M. Moghimi, A. C. Hunter, and J. C. Murray, " Long-circulating and target-specific nanoparticles: Theory to practice., " Pharmacol. Rev. 53, 283-318 (2001).
22. S. M. Moghimi and J. Szebeni, " Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization, and protein-binding properties., " Prog. Lipid Res. 42, 463-478 (2003).
23. S. M. Moghimi and A. C. Hunter, " Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups., " Pharm. Res. 18, 1-8 (2001).
24. E. D. Owens, III and N. A. Peppas, " Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles., " Int. J. Pharm. 307, 93-102 (2006).
25. S. M. Moghimi, A. C. Hunter, and J. C. Murray, " Nanomedicine: Current status and future prospect., " FASEB J. 19, 311-330 (2005).
26. R. Gref, M. Luck, P. Quellec, M. Marchand, E. Dellacherie, S. Harnish, T. Blunk, and R. H. Muller, " Stealth corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption., " Colloids Surf., B 18, 301-313 (2000).
27. Y. Yi, J. H. Kim, H.-W. Kang, H. S. Oh, S. W. Kim, and M. H. Seo, " A polymeric nanoparticle consisting of mPEG-PLA-Toco and PLMA-COONa as a drug carrier: improvements in cellular uptake and biodistribution., " Pharm. Res. 22, 200-208 (2005).
28. C. C. Berry and A. S. G. Curtis, " Functionalisation of magnetic nanoparticles for applications in biomedicine., " J. Leukoc Biol. 78, 585-594 (2005).
29. S. E. McNeil, " Nanotechnology for the biologist., " J. Leukoc Biol. 78, 585-594 (2005).
30. M. Yokoyama, " Drug targeting with nano-sized carrier systems., " J. Artif. Organs 8, 77-84 (2005).
31. W. J. Parak, T. Pellegrino, and C. Plank, " Labelling of cells with quantum dots., " Nanotechnology 16, R9-R25 (2005).
32. X. Wu, H. Liu, K. N. Haley, J. A. Treadway, J. P. Larson, N. Ge, F. Peale, and M. P. Bruchez, " Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots., " Nat. Biotechnol. 21, 41-46 (2003).
33. X. Gao, Y. Cui, R. M. Levenson, L. W. K. Chung, and S. Nie, " In vivo cancer targeting and imaging with semiconductor quantum dots., " Nat. Biotechnol. 22, 969-976 (2004).
34. M. N. Rhyner, A. M. Smith, X. Gao, H. Mao, L. Yang, and S. Nie, " Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging., " Nanomedicine 1, 209-217 (2006).
35. J. T. Kemshead and J. Ugelstad, " Magnetic separation techniques: their application to medicine., " Mol. Cell. Biochem. 67, 11-18 (1985).
36. V. Choesmel, P. Anract, H. Hoifodt, J. P. Thiery, and N. Blin, " A relevant immunomagnetic assay to detect and characterize epithelial cell adhesion molecule-positive cells in bone marrow from patients with breast carcinoma: immunomagnetic purification of micrometastases., " Cancer 101, 693-703 (2004).
37. C. Loo, A. Lowery, N. Halas, J. West, and R. Drezek, " Immunotargeted nanoshells for integreted cancer imaging and therapy., " Nano Lett. 5, 709-711 (2005).
38. L. R. Hirsch, R. J. Stafford, J. A. Bankson, S. R. Sershen, B. Rivera, R. E. Price, J. D. Hazle, N. J. Halas, and J. L. West, " Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance., " Proc. Natl. Acad. Sci. U.S.A. 100, 13549-13554 (2003).
39. G. Wang, T. Huang, R. W. Murray, L. Menard, and R. G. Nuzzo, " Near-IR luminescence of monolayer-protected metal clusters., " J. Am. Chem. Soc. 127, 812-813 (2005).
40. V. E. Nuttens, A.-C. Wera, V. Bouchat, and S. Lucas, " Determination of biological vector characteristics and nanoparticle dimensions for radioimmunotherapy with radioactive nanoparticles., " Appl. Radiat. Isot. (accepted).
41. D. Ribatti, A. Vacca, and F. Dammacco, " The role of vascular phase in solid tumor growth: A historical review., " Neoplasia 1, 293-302 (1999).
42. J. Folkman, E. Merler, C. Abernathy, and G. Williams, " Isolation of a tumor factor responsible or angiogenesis., " J. Exp. Med. 133, 275-288 (1971).
43. R. M. Sutherland, " Cell and environment interactions in tumor microregions: The multicell spheroid model., " Science 240, 177-184 (1988).
44. M. Cremonesi, M. Ferrari, L. Bodei, G. Tosi, and G. Paganelli, " Systemic and locoregional dosimetry in receptor radionuclide therapy with peptides., " Q. J. Nucl. Med. Mol. Imaging 50, 288-295 (2006).
45. R. W. Howell, D. V. Rao, and K. S. R. Sastry, " Macroscopic dosimetry for radioimmuno-therapy: Nonuniform activity distributions in solid tumors., " Med. Phys. 16, 66-74 (1989).
46. E. B. Van Dieren, M. A. B. D. Plaizier, A. Van Lingen, J. C. Roos, G. W. Barendsen, and G. J. J. Teule, " Absorbed dose distribution of the auger emitters 67Ga and 125I and the Β -emitters 67Cu, 90Y, 131I, and 186Re as a function of tumor size, uptake, and intracellular distributin., " Int. J. Radiat. Oncol., Biol., Phys. 36, 197-204 (1996).
47. ICRU Report 44, " Tissue substitutes in radiation dosimetry and measurement., " (International Commission on Radiation Units and Measurements, Bethesda, MD, 1989), p 22.
48. S. Lin, C.-K. Lee, Y.-H. Lin, S.-Y. Lee, B.-C. Sheu, J.-C. Tsai, and S.-M. Hsu, " Homopolyvalent antibody-antigen interaction kinetic studies with use of a dual-polarization interferometric biosensor., " Biosens. Bioelectron. 22, 715-721 (2006).
49. A. S. Paulo and R. Garcia, " High-resolution imaging of antibodies by tapping-mode atomic force microscopy: attractive and repulsive tip-sample interaction regimes., " Biophys. J. 78, 1599-1605 (2006).
50. L. Cser, I. A. Gladkib, F. Franek, and Yu. M. Ostanevich, " Investigation of antibody structures by scattering techniques., " Colloid Polym. Sci. 259, 625-640 (1981).
51. H. F. Dvorak, J. A. Nagy, and A. M. Dvorak, " Structure of solid tumors and their vasculature: Implications for therapy with monoclonal antibodies., " Cancer Cells 3, 77-85 (1991).
52. B. Döme, S. Paku, B. Somlai, and J. Timar, " Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance., " J. Pathol. 197, 355-362 (2002).
53. J. A. M. Belin, P. J. van Diest, and J. P. A. Baak, " Relation between vascularization and proliferation in invasive breast cancer., " J. Pathol. 189, 309-318 (1999).
54. C. Schlueter, H. Weber, B. Meyer, P. Rogalla, K. Röser, S. Hauke, and J. Bullerdiek, " Angiogenic signaling through hypoxia., " Am. J. Pathol. 166, 1259-1263 (2005).
55. D.-S. Lee, H. Rieger, and K. Bartha, " Flow correlated percolation during vascular remodeling in growing tumors., " Phys. Rev. Lett. 96, 058104 (2006).
56. K. Bartha and H. Rieger, " Vascular network remodeling via vessel cooption, regression and growth in tumors., " J. Theor. Biol. 241, 903-918 (2006).
57. J. L. Humm and L. M. Cobb, " Nonuniformity of tumor dose in radioimmunotherapy., " J. Nucl. Med. 31, 75-83 (1990).
58. D. B. Pelowitz,, ed., " MCNPX User's Manual, Version 2.5.0., " LA-CP-05-0369 (2005).
59. N. Reynaert, H. Palmans, H. Thierens, and R. Jeraj, " Parameter dependence of the MCNP electron transport in determining dose distributions., " Med. Phys. 29, 2446-2454 (2002).
60. D. R. Schaart, J. Th.M. Jansen, J. Zoetelief, and P. F. A. de Leege, " A comparison of MCNP4C electron transport with ITS 3.0 and experiment at incident energies between 100 keV and 20 MeV: influence of voxel size, substeps and energy indexing algorithm., " Phys. Med. Biol. 47, 1459-1484 (2002).
61. P. Karnami and K. Kairemo, " Targeting endothelial growth with monoclonal antibodies against Tie-1 kinase in mouse models., " Clin. Cancer Res. 9, 3821s-3826s (2003).
62. A. Jekunen, K. Kairemo, and P. Karnami, " In vivo modulators of antibody kinetics., " Acta Oncol. 35, 267-271 (1996).
63. S. Palm, R. M. Enmon, Jr., C. Matei, K. S. Kolbert, S. Xu, P. B. Zanzonico, R. L. Finn, J. A. Koutcher, S. M. Larson, and G. Sgouros, " Pharmacokinetics and biodistribution of Y86 -Trastuzumab for Y90 dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI., " J. Nucl. Med. 44, 1148-1155 (2003).
64. F. T. Lee, A. Rigopoulos, C. Hall, K. Clarke, S. H. Cody, F. E. Smyth, Z. Liu, M. W. Brechbiel, N. Hanai, E. C. Nice, B. Catimel, A. W. Burgess, S. Welt, G. Ritter, L. J. Old, and A. M. Scott, " Specific localization, gamma camera imaging, and intracellular trafficking of radiolabeled chimeric anti- GD3 ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts., " Cancer Res. 61, 4474-4482 (2001).
65. C.-H. Chang, R. M. Sharkey, E. A. Rossi, H. Karacay, W. McBride, H. J. Hansen, J.-F. Chatal, J. Barbet, and D. M. Goldenberg, " Molecular advances in pretargeting radioimunotherapy with bispecific antibodies., " Mol. Cancer Ther. 1, 553-563 (2002).
66. K. Tobinai, Y. Kobayashi, and M. Narabayashi, " Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma., " Ann. Oncol. 9, 527-534 (1998).
67. D. M. Goldenberg, David M. Goldenberg, R. M. Sharkey, G. Paganelli, J. Barbet, and J.-F. Chatal, " Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy., " J. Clin. Oncol. 24, 823-834 (2006).